Eckert Ziegler and AtomVie Make Progress with Global Lutetium-177 Supply Agreement

Significant Collaboration for Radiopharmaceuticals

Eckert Ziegler SE and AtomVie Global Radiopharma Inc. have officially entered into a major global supply agreement centered around Lutetium-177, a crucial isotope for the production of radiopharmaceuticals. This agreement showcases both companies' commitment to advancing the application of nuclear medicine and providing high-quality therapeutic solutions.

Strengthening Production Capacities

The partnership aims to support AtomVie’s Contract Development and Manufacturing Organization (CDMO) activities by supplying high-grade, non-carrier-added Lutetium-177 chloride (n.c.a. Lu-177). The use of Theralugand®, Eckert Ziegler’s flagship product, is especially significant as it will help AtomVie enhance its production capabilities.

According to Dr. Harald Hasselmann, CEO of Eckert Ziegler SE, "This partnership not only allows us to contribute to the development of therapeutic solutions in nuclear medicine but also reinforces our commitment to supporting innovative healthcare approaches worldwide."

Dynamic and Flexible Agreement Structure

The scope of this collaboration spans both early and late development stages, thereby enabling a responsive approach to the diverse needs of pharmaceutical partners. This flexibility will enhance AtomVie’s ability to adapt to varying regulatory requirements while still meeting demands for their Lutetium-177-based radiopharmaceutical products.

Bruno Paquin, CEO of AtomVie, highlighted that this collaboration is a critical step in ensuring their global partners can access the necessary support to develop pioneering treatments based on Lutetium-177. As AtomVie prepares to launch a new facility later this year, this agreement aims to ensure consistent and high-quality production services.

Contributions to Global Health

By partnering with Eckert Ziegler, AtomVie takes a significant leap towards enhancing the lives of patients through innovative radiopharmaceuticals. As the development of new therapies progresses, both companies anticipate contributing to the expansion of treatment options available for various medical conditions.

About Eckert Ziegler

Eckert Ziegler is a leader in the manufacture of isotopic technologies crucial for nuclear medicine and radiation therapy. With over 1,000 employees, it offers an extensive array of products and services ranging from initial development phases to commercial distribution. Eckert Ziegler’s stock (ISIN DE0005659700) is listed on the TecDAX of the Deutsche Börse.

About AtomVie Global Radiopharma

As a recognized Contract Development and Manufacturing Organization (CDMO), AtomVie excels in the GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. AtomVie is dedicated to providing a full suite of scientific, technical, regulatory, quality, and logistical services to assist in the development of radiopharmaceuticals, collaborating with clients across more than 25 countries.

Final Thoughts

The collaboration between Eckert Ziegler and AtomVie represents a significant advancement in the field of radiopharmaceuticals. By securing a reliable supply of Lutetium-177, both companies are poised to lead the charge in developing innovative treatment options, thereby contributing to the improvement of patient outcomes on a global scale.